AbbVie Past Earnings Performance

Past criteria checks 1/6

AbbVie has been growing earnings at an average annual rate of 5.5%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 10.7% per year. AbbVie's return on equity is 78.4%, and it has net margins of 9.6%.

Key information

5.5%

Earnings growth rate

2.1%

EPS growth rate

Biotechs Industry Growth14.8%
Revenue growth rate10.7%
Return on equity78.4%
Net Margin9.6%
Next Earnings Update30 Oct 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AbbVie makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WBAG:ABBV Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2455,0005,29813,1347,405
31 Mar 2454,4035,95112,9737,189
31 Dec 2354,3184,82012,9047,038
30 Sep 2355,1386,47012,4536,897
30 Jun 2356,0238,63512,2606,785
31 Mar 2356,7417,53512,2016,661
31 Dec 2258,05411,78212,0846,487
30 Sep 2257,81913,34312,1166,518
30 Jun 2257,34912,56911,9886,551
31 Mar 2256,72512,40711,9436,692
31 Dec 2156,19711,46811,8726,820
30 Sep 2155,1697,46511,0546,829
30 Jun 2153,7296,59910,8606,761
31 Mar 2150,1955,09210,9556,418
31 Dec 2045,8044,5569,8676,003
30 Sep 2040,6507,3249,4295,902
30 Jun 2036,2276,9068,2885,582
31 Mar 2034,0578,3956,7605,467
31 Dec 1933,2667,8426,7635,377
30 Sep 1932,8673,2326,4875,260
30 Jun 1932,6244,0936,7655,273
31 Mar 1932,6475,3336,8735,304
31 Dec 1832,7535,6577,3535,259
30 Sep 1832,1877,5316,9725,242
30 Jun 1830,9466,4196,6235,202
31 Mar 1829,6126,3526,3035,109
31 Dec 1728,2165,2836,2485,007
30 Sep 1727,2736,6155,9584,789
30 Jun 1726,7106,5825,7994,667
31 Mar 1726,2186,2785,8614,562
31 Dec 1625,6385,9235,8374,385
30 Sep 1625,2426,0485,7334,178
30 Jun 1624,7545,6905,7244,472
31 Mar 1623,7775,4485,6464,236
31 Dec 1522,8595,1185,6634,101
30 Sep 1521,9112,7906,0593,978
30 Jun 1520,9862,0646,1783,390
31 Mar 1520,4371,8026,1333,336
31 Dec 1419,9601,7656,0243,297
30 Sep 1419,6193,6865,4133,201
30 Jun 1419,2584,1445,1363,103
31 Mar 1419,0244,1145,1132,978
31 Dec 1318,7904,1025,3522,840

Quality Earnings: ABBV has a large one-off loss of $8.9B impacting its last 12 months of financial results to 30th June, 2024.

Growing Profit Margin: ABBV's current net profit margins (9.6%) are lower than last year (15.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ABBV's earnings have grown by 5.5% per year over the past 5 years.

Accelerating Growth: ABBV's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ABBV had negative earnings growth (-38.6%) over the past year, making it difficult to compare to the Biotechs industry average (-13.8%).


Return on Equity

High ROE: Whilst ABBV's Return on Equity (78.43%) is outstanding, this metric is skewed due to their high level of debt.


Return on Assets


Return on Capital Employed


Discover strong past performing companies